Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience

Wojciech Straś; Joanna Gotlib; Piotr Małkowski; Dariusz Wasiak; Andrzej Śliwczyński; Mariusz Panczyk; Olga Tronina; Melania Brzozowska

doi:10.12659/MSM.931856

31 August 2021 : Clinical Research

Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience

Wojciech Straś^1ACDE, Joanna Gotlib^2ACEF, Piotr Małkowski^3ACDEFG*, Dariusz Wasiak^3CDE, Andrzej Śliwczyński^3BCDE, Mariusz Panczyk^2ACDE, Olga Tronina^4EF, Melania Brzozowska^5BCD

DOI: 10.12659/MSM.931856

Med Sci Monit 2021; 27:e931856

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Therapy duration summary.

		Comments
Minimum	14 days
Maximum	2800 days
Median (50% patients)	111 days
Mean	225.8 days	95% CL: 207.71–243.97
Observation period	2946 days

Back to the Article

Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience

Your Privacy